medigraphic.com
ISSN 2305-7939 (Electronic)

2022, Number 2

<< Back Next >>

RCU 2022; 11 (2)

Andean phytotherapy: systematic review of its application in prostate cancer

Solano PRJ, Simbaina SJC

Language: Spanish
References: 29
Page: 16-25
PDF size: 362.28 Kb.


ABSTRACT

Introduction: Prostate cancer is a serious problem in adult men. Although it is not a fatal disease, its incidence is increasing more and more. For recovery, different therapies are applied, among them phytotherapy becomes relevant. Objective: Analyze phytotherapy techniques used in the Andean region for the prevention and treatment of prostate cancer. Methods: A systematic review of the scientific evidence published from 2011 to 2021 was carried out; the following search terms were used: Urology, “Urology”; prostate cancer, “prostate cancer”; phytotherapy, “phytotherapy” and Andean phytotherapy, “Andean herbal medicine”. The databases consulted were: ISI - Web of Science, Science Direct, PubMed, SciELO and Google Scholar. In vitro/in vivo studies of animal and human models were included. Literature in a language other than Spanish was excluded. Results: Eleven respective studies, submitted to the analysis, suggest satisfactory results at the experimental level. Likewise, endemic species of the Andean region such as Chuquiraga spinosa (chuquirahua), Xanthium spinosum (casha marucha), and Tropaeolum tuberosum (mashua) have shown promising results as an alternative and complementary treatment for urogenital conditions of the male population. Conclusions: The plants studied according to phytotherapy in the Andean region seem promising for the prevention and treatment of prostate cancer, and it is suggested to use them together with conventional medicine. However, the research consulted is in the experimental phase, therefore, there are not yet sufficient elements for its recommendation.


REFERENCES

  1. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb PerspectMed. 2018 [acceso 03/07/2021];8(12):a030361. Disponible en:https://www.perspectivesinmedicine.cshlp.org/content/8/12/a030361.short

  2. Rawla P. Epidemiology of prostate Cancer. World J Oncol. 2019;10(2):63-89. DOI:https://doi.org/10.14740/wjon1191

  3. Bhatt NR, Davis NF, Witjes WP, Bjartell A, Caris C, Patel A, et al. Contemporary use of phytotherapy in patientswith lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION Europeanregistry. World J Urol. 2021 [acceso 10/07/2021];39(7):2661-7. Disponible en:https://link.springer.com/article/10.1007/s00345-020-03480-w

  4. Repetto E, Sosa A, Martin Revol R, Metrebian E, Metrebian S. Relación de prostatitis en la aparición del cáncerde próstata y la hiperplasia benigna prostática. Rev Cubana Urol. 2019 [acceso 12/07/2021];8(1):22-33.Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/502

  5. Leslie SW, Soon Sutton TL, Sajjad H, Siref LE. Prostate Cancer. En: StatPearls [Internet]. Treasure Island, Florida:StatPearls Publishing; 2021 [acceso 15/07/2021]. Disponible en:http://www.ncbi.nlm.nih.gov/books/NBK470550/

  6. Shivajirao CS, B.Bawage S, B.Bawage N. Herbal medicine and its uses. IJRPR. 2021 [acceso25/07/2021];2(10):949-50. Disponible en: https://ijrpr.com/uploads/V2ISSUE10/IJRPR1600.pdf

  7. Soria N. Las plantas medicinales y su aplicación en la salud pública. Rev Salud Pública Parag. 2018;8(1):7-8.DOI: https://doi.org/10.18004/rspp.2018.junio.7-8

  8. Bounda GA. Phytotherapy of prostate cancer: how far are we? Clin Oncol Case Rep. 2018 [acceso12/08/2021];1(1). Disponible en: https://www.scitechnol.com/peer-review/phytotherapy-of-prostatecancerhow-far-are-we-IzBq.php?article_id=7710

  9. Seisen T, Drouin SJ, Rouprêt M. Hipertrofia benigna de próstata. EMC - Tratado de Medicina. 2017; 21(2):1-

  10. DOI: https://www.doi.org/10.1016/S1636-5410(17)84251-310. Aguaiza Quizhpilema J, Simbaina Solano JC. Uso de plantas medicinales y conocimientos ancestralesen las comunidades rurales de la provincia de Cañar, Ecuador. Rev CENIC Cienc Biol. 2021 [acceso09/09/2021];52(3):223-36. Disponible en:https://revista.cnic.edu.cu/index.php/RevBiol/article/view/1210

  11. El-Readi MZ, Al-Abd AM, Althubiti MA, Almaimani RA, Al-Amoodi HS, Ashour ML, et al. Multiplemolecular mechanisms to overcome multidrug resistance in cancer by natural secondarymetabolites. Front Pharmacol. 2021; 12:942. DOI: https://doi.org/10.3389/fphar.2021.658513

  12. Tarkang PA, Appiah Opong R, Ofori MF, Ayong LS, Nyarko AK. Application of multi-targetphytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarkeridentification. Biomark Res. 2016 [acceso 26/12/2021];4(1):25. Disponible en:https://link.springer.com/article/10.1186/s40364-016-0077-0

  13. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancertreatment: from preclinical studies to clinical practice. Front Pharmacol. 2020; 10:1614. DOI:https://doi.org/10.3389/fphar.2019.01614

  14. Stolarczyk M, Piwowarski JP, Granica S, Stefańska J, Naruszewicz M, Kiss AK. Extracts from epilobiumsp. herbs, their components and gut microbiota metabolites of epilobium ellagitannins, urolithins,inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion.Phytother Res. 2013; 27(12):1842-8. DOI: https://doi.org/10.1002/ptr.4941

  15. Wehrberger C, Dreikorn K, Schmitz Dräger BJ, Oelke M, Madersbacher S. Phytotherapy of benignprostate syndrome and prostate cancer: better than placebo. Urologe A. 2012 [acceso 03/01/2022];51(12):1674-82. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23160605/

  16. Elterman DS, Lawrentschuk N, Guns E, Hersey K, Adomat H, Wood CA, et al. Investigatingcontamination of phytotherapy products for benign prostatic hyperplasia with α-blockers and 5α-reductase inhibitors. J Urol. 2010; 183(5):2085-9. DOI: https://doi.org/10.1016/j.juro.2009.12.097

  17. Kim SM, Park JH, Kim KD, Nam D, Shim BS, Kim SH, et al. Brassinin induces apoptosis in PC-3 humanprostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades. PhytotherRes. 2014;28(3):423-31. DOI: https://doi.org/10.1002/ptr.5010

  18. Asare GA, Ngala RA, Afriyie D, Adjei S, Nyarko A, Anang Quartey Y, et al. Calcium - magnesiumimbalance implicated in benign prostatic hyperplasia and restoration by a phytotherapeutic drug –Croton membranaceus Müll.Arg. BMC Complement Altern Med. 2017 [acceso 05/01/2022];17(1):152. Disponible en:https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-017-1663-x

  19. Deveci E, Cayan GT, Karakurt S, Duru ME. Antioxidant, cytotoxic, and enzyme inhibitory activities ofagropyron repens and crataegus monogyna species. Eur J Biol. 2020 [acceso 06/01/2022];79(2):98-105. Disponible en: https://dergipark.org.tr/en/pub/iufsjb/issue/55111/844411

  20. Arroyo Acevedo J, Herrera Calderón O, Chávez Asmat R, Anampa Guzmán A, Chumpitaz Cerrate V,Enciso Roca E. Protective effect of Chuquiraga spinosa extract on N-methyl-nitrosourea (NMU)induced prostate cancer in rats. Prostate Int. 2017; 5(2):47-52. DOI:https://doi.org/10.1016/j.prnil.2017.01.005

  21. Guerrero Bonilla DA, Granda Albuja MG, Guevara M, Iturralde GA, Jaramillo Vivanco T, Giampieri F,et al. Bioactive compounds and antioxidant capacity of Chuquiraga jussieui J.F.Gmel from thehighlands of Ecuador. Nat Prod Res. 2020;34(18):2652-5. DOI:https://doi.org/10.1080/14786419.2018.1548450

  22. Verma V, Sharma V, Singh V, Kumar R, Khan MF, Singh AK, et al. Labda-8(17),12,14-trien-19-oic acidcontained in fruits of Cupressus sempervirens suppresses benign prostatic hyperplasia in rat and invitro human models through inhibition of androgen and STAT-3 signaling. Phytother Res.2014;28(8):1196-203. DOI: https://doi.org/10.1002/ptr.5114

  23. Boeing T, Tafarelo Moreno KG, Gasparotto Junior A, Mota da Silva L, de Souza P. Phytochemistry andpharmacology of the genus equisetum (equisetaceae): A narrative review of the species withtherapeutic potential for kidney diseases. J Evid Based Complementary Altern Med. 2021; 2021:e6658434. DOI: https://doi.org/10.1155/2021/6658434

  24. Mahboubi M. Urtica dioica in the management of benign prostate hyperplasia (BPH). J Nat Prod.2019;10(5):535-42. DOI: https://doi.org/10.2174/2210315509666190723125509

  25. Güez CM, Waczuk EP, Pereira KB, Querol MVM, Rocha JBT da, de Oliveira LFS. In vivo and in vitrogenotoxicity studies of aqueous extract of Xanthium spinosum. Braz J Pharm Sci. 2012;48:461-7. DOI:https://doi.org/10.1590/S1984-82502012000300013

  26. Xu YM, Wijeratne EMK, Babyak AL, Marks HR, Brooks AD, Tewary P, et al. Withanolides fromaeroponically grown Physalis peruviana and their selective cytotoxicity to prostate cancer and renalcarcinoma cells. J Nat Prod. 2017; 80(7):1981-91. DOI:https://doi.org/10.1021/acs.jnatprod.6b01129

  27. Karimi E, Oskoueian E, Karimi A, Noura R, Ebrahimi M. Borago officinalis L. flower: a comprehensivestudy on bioactive compounds and its health-promoting properties. J Food Meas Charact. 2018[acceso 08/01/2022];12(2):826-38. Disponible en:https://link.springer.com/article/10.1007/s11694-017-9697-9

  28. Chung KS, Shin SJ, Lee NY, Cheon SY, Park W, Sun SH, et al. Anti-proliferation effects of garlic (Alliumsativum L.) on the progression of benign prostatic hyperplasia. Phytother Res. 2016;30(7):1197-203.DOI: https://doi.org/10.1002/ptr.5637

  29. Flores E, Apaza J, Calsina WC, Quille G, Huanca F, Coloma A, et al. Conocimiento ancestral en lacuración de la próstata a base de isaño (Tropaeolum tuberosum). Idesia (Arica). 2020;38(4):7-16.DOI: https://doi.org/10.4067/S0718-34292020000400007




2020     |     www.medigraphic.com